Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders

[1]  A. Punga,et al.  Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders , 2022, The Lancet Neurology.

[2]  A. Marx,et al.  Advances in the understanding of disease mechanisms of autoimmune neuromuscular junction disorders , 2022, The Lancet Neurology.

[3]  Meng Pu,et al.  Effectiveness and Safety of Rituximab for Refractory Myasthenia Gravis: A Systematic Review and Single-Arm Meta-Analysis , 2021, Frontiers in Neurology.

[4]  Huan Yang,et al.  To Be or Not To Be Vaccinated: That Is a Question in Myasthenia Gravis , 2021, Frontiers in Immunology.

[5]  J. Statland,et al.  Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial , 2021, The Lancet Neurology.

[6]  C. Chao,et al.  COVID-19 vaccines: concerns beyond protective efficacy and safety , 2021, Expert review of vaccines.

[7]  J. Bednařík,et al.  Predictive factors for a severe course of COVID‐19 infection in myasthenia gravis patients with an overall impact on myasthenic outcome status and survival , 2021, European journal of neurology.

[8]  P. Bini,et al.  COVID‐19 in patients with myasthenia gravis: Epidemiology and disease course , 2021, Muscle & nerve.

[9]  H. Wiendl,et al.  Zilucoplan: An Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibody–Positive Generalized Myasthenia Gravis , 2021, Expert opinion on investigational drugs.

[10]  M. Sermer,et al.  Myasthenia Gravis and Pregnancy: Toronto Specialty Center Experience , 2021, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[11]  M. Del Sette,et al.  Myasthenia gravis associated with anti‐MuSK antibodies developed after SARS‐CoV‐2 infection , 2021, European journal of neurology.

[12]  Shota Yamamoto,et al.  Pathological Mechanisms of Bortezomib-Induced Peripheral Neuropathy , 2021, International journal of molecular sciences.

[13]  H. Wiendl,et al.  Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension , 2020, Neurology.

[14]  T. Segura,et al.  Ocular myasthenia gravis and risk factors for developing a secondary generalisation: Description of a Spanish series. , 2020, Neurologia.

[15]  Jacqueline Palace,et al.  International Consensus Guidance for Management of Myasthenia Gravis , 2020, Neurology.

[16]  Jacqueline A Palace,et al.  Myasthenia gravis. , 2020, Nature reviews. Disease primers.

[17]  V. Bril,et al.  Chronic immunoglobulin maintenance therapy in myasthenia gravis , 2020, European journal of neurology.

[18]  Patricia M. Sikorski,et al.  Monoclonal Antibody-Based Therapies for Myasthenia Gravis , 2020, BioDrugs.

[19]  D. Patel,et al.  Neonatal Fc receptor in human immunity: Function and role in therapeutic intervention. , 2020, The Journal of allergy and clinical immunology.

[20]  Shigeaki Suzuki,et al.  Reappraisal of Oral Steroid Therapy for Myasthenia Gravis , 2020, Frontiers in Neurology.

[21]  M. Dalakas.  Progress in the therapy of myasthenia gravis: getting closer to effective targeted immunotherapies , 2020, Current opinion in neurology.

[22]  D. Centonze,et al.  Myasthenia Gravis Associated With SARS-CoV-2 Infection , 2020, Annals of Internal Medicine.

[23]  Jacqueline Palace,et al.  Management of Juvenile Myasthenia Gravis , 2020, Frontiers in Neurology.

[24]  E. Orenbuch-Harroch,et al.  Description of 3 patients with myasthenia gravis and COVID-19 , 2020, Journal of the Neurological Sciences.

[25]  H. Kushlaf.  COVID‐19 in muscle‐specific kinase myasthenia gravis: A case report , 2020, Muscle & nerve.

[26]  A. Lascano,et al.  Management of patients with generalised myasthenia gravis and COVID-19: four case reports , 2020, Journal of Neurology, Neurosurgery, and Psychiatry.

[27]  V. Bril,et al.  Novel Treatments in Myasthenia Gravis , 2020, Frontiers in Neurology.

[28]  J. Verschuuren,et al.  Lung cancer prediction in Lambert-Eaton myasthenic syndrome in a prospective cohort , 2020, Scientific Reports.

[29]  T. Mozaffar,et al.  Update on immune‐mediated therapies for myasthenia gravis , 2020, Muscle & nerve.

[30]  A. Guidon,et al.  COVID‐19 in patients with myasthenia gravis , 2020, Muscle & nerve.

[31]  J. Sejvar,et al.  Neurological associations of COVID-19 , 2020, The Lancet Neurology.

[32]  H. Wiendl,et al.  Response to eculizumab in patients with myasthenia gravis recently treated with chronic IVIg: a subgroup analysis of REGAIN and its open-label extension study , 2020, Therapeutic advances in neurological disorders.

[33]  H. Wiendl,et al.  Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic , 2020, Journal of the Neurological Sciences.

[34]  V. Bril,et al.  New insights into very-late-onset myasthenia gravis , 2020, Nature Reviews Neurology.

[35]  N. Hattori,et al.  Suitable indications of eculizumab for patients with refractory generalized myasthenia gravis , 2020, Therapeutic advances in neurological disorders.

[36]  M. Benatar,et al.  Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis , 2020, JAMA neurology.

[37]  Stefan Roepcke,et al.  Safety, tolerability, pharmacokinetics and pharmacodynamics of the anti‐CD38 cytolytic antibody TAK‐079 in healthy subjects , 2020, British journal of clinical pharmacology.

[38]  Jacqueline Palace,et al.  242nd ENMC International Workshop: Diagnosis and management of juvenile myasthenia gravis Hoofddorp, the Netherlands, 1–3 March 2019 , 2020, Neuromuscular Disorders.

[39]  E. V. van Zwet,et al.  Long‐term follow‐up, quality of life, and survival of patients with Lambert‐Eaton myasthenic syndrome , 2019, Neurology.

[40]  D. Marimpietri,et al.  CD38, a Receptor with Multifunctional Activities: From Modulatory Functions on Regulatory Cell Subsets and Extracellular Vesicles, to a Target for Therapeutic Strategies , 2019, Cells.

[41]  Jacqueline Palace,et al.  Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder. , 2019, The New England journal of medicine.

[42]  J. Palace,et al.  Paediatric myasthenia gravis: Prognostic factors for drug free remission , 2019, Neuromuscular Disorders.

[43]  V. Bril,et al.  Current pharmacotherapeutic options for myasthenia gravis , 2019, Expert opinion on pharmacotherapy.

[44]  P. van Damme,et al.  A Phase 3 Multicenter, Prospective, Open-Label Efficacy and Safety Study of Immune Globulin (Human) 10% Caprylate/Chromatography Purified in Patients with Myasthenia Gravis Exacerbations , 2019, European Neurology.

[45]  A. Zuercher,et al.  Next-generation Fc receptor-targeting biologics for autoimmune diseases. , 2019, Autoimmunity reviews.

[46]  M. Motomura,et al.  MGTX extension study longitudinally favors early thymectomy in non-thymomatous young-adult patients with AChR antibody-positive myasthenia gravis. , 2019, Annals of translational medicine.

[47]  P. Suñé,et al.  Intravenous immunoglobulin to prevent myasthenic crisis after thymectomy and other procedures can be omitted in patients with well-controlled myasthenia gravis , 2019, Therapeutic advances in neurological disorders.

[48]  P. van Damme,et al.  Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis , 2019, Neurology.

[49]  Yongbo Zhang,et al.  A case report of disseminated nocardiosis with ocular involvement in a myasthenia gravis patient and literature review , 2019, BMC Neurology.

[50]  M. Benatar,et al.  Long‐term safety and efficacy of eculizumab in generalized myasthenia gravis , 2019, Muscle & nerve.

[51]  G. Rimmelzwaan,et al.  A prospective, double-blind, randomized, placebo-controlled study on the efficacy and safety of influenza vaccination in myasthenia gravis. , 2019, Vaccine.

[52]  R. Wells,et al.  Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. , 2019, Blood.

[53]  K. McKeage.  Ravulizumab: First Global Approval , 2019, Drugs.

[54]  L. Salazar,et al.  Autologous hematopoietic stem cell transplantation in a patient with refractory seropositive myasthenia gravis: A case report , 2019, Neuromuscular Disorders.

[55]  U. Grittner,et al.  Bortezomib in antibody-mediated autoimmune diseases (TAVAB): study protocol for a unicentric, non-randomised, non-placebo controlled trial , 2019, BMJ Open.

[56]  A. Manning,et al.  M281, an Anti‐FcRn Antibody: Pharmacodynamics, Pharmacokinetics, and Safety Across the Full Range of IgG Reduction in a First‐in‐Human Study , 2018, Clinical pharmacology and therapeutics.

[57]  S. Côté,et al.  Characterization of the in vitro and in vivo properties of CFZ533, a blocking and non‐depleting anti‐CD40 monoclonal antibody , 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[58]  C. Ponticelli,et al.  Fetal Toxicity of Immunosuppressive Drugs in Pregnancy , 2018, Journal of clinical medicine.

[59]  A. Meisel,et al.  Generalization after ocular onset in myasthenia gravis: a case series in Germany , 2018, Journal of Neurology.

[60]  N. Gilhus,et al.  Maternal myasthenia gravis represents a risk for the child through autoantibody transfer, immunosuppressive therapy and genetic influence , 2018, European journal of neurology.

[61]  A. Punga,et al.  The impact of physical exercise on neuromuscular function in Myasthenia gravis patients , 2018, Medicine.

[62]  D. Sanders,et al.  Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis , 2018, Neurology.

[63]  Zhao-Xue Yu,et al.  Design and preclinical characterization of ALXN1210: A novel anti-C5 antibody with extended duration of action , 2018, PloS one.

[64]  I. Sunwoo,et al.  3,4-Diaminopyridine for the treatment of myasthenia gravis with electrophysiological patterns of Lambert-Eaton myasthenic syndrome , 2018, Journal of Clinical Neuroscience.

[65]  J. Lindstrom,et al.  Acetylcholine receptor–specific immunosuppressive therapy of experimental autoimmune myasthenia gravis and myasthenia gravis , 2018, Annals of the New York Academy of Sciences.

[66]  R. Mantegazza,et al.  When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies , 2018, Therapeutic advances in neurological disorders.

[67]  Jacqueline A Palace,et al.  Therapeutic strategies for congenital myasthenic syndromes , 2018, Annals of the New York Academy of Sciences.

[68]  J. Howard.  Myasthenia gravis: the role of complement at the neuromuscular junction , 2018, Annals of the New York Academy of Sciences.

[69]  G. L. Masson,et al.  Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. , 2017, The Lancet. Neurology.

[70]  U. Dalgas,et al.  Exercise in myasthenia gravis: A feasibility study of aerobic and resistance training , 2017, Muscle & nerve.

[71]  M. Benatar,et al.  Rituximab as treatment for anti-MuSK myasthenia gravis , 2017, Neurology.

[72]  M. Emtner,et al.  Physical exercise in myasthenia gravis is safe and improves neuromuscular parameters and physical performance‐based measures: A pilot study , 2017, Muscle & nerve.

[73]  F. Piehl,et al.  Beneficial effect of tocilizumab in myasthenia gravis refractory to rituximab , 2017, Neuromuscular Disorders.

[74]  L. Tuan,et al.  Progressive cutaneous Cryptococcosis complicated with meningitis in a myasthenia gravis patient on long-term immunosuppressive therapy – a case report , 2017, BMC Infectious Diseases.

[75]  C. Vrinten,et al.  Ephedrine treatment for autoimmune myasthenia gravis , 2017, Neuromuscular Disorders.

[76]  Mahbobeh Oroei,et al.  A comparison between IVIG and plasma exchange as preparations before thymectomy in myasthenia gravis patients , 2016, Acta Neurologica Belgica.

[77]  Hidekazu Suzuki,et al.  Early fast‐acting treatment strategy against generalized myasthenia gravis , 2017, Muscle & nerve.

[78]  F. Piehl,et al.  Successful autologous haematopoietic stem cell transplantation for refractory myasthenia gravis – a case report , 2017, Neuromuscular Disorders.

[79]  A. Traboulsee,et al.  Ocrelizumab versus Interferon Beta‐1a in Relapsing Multiple Sclerosis , 2017, The New England journal of medicine.

[80]  R. Herbst,et al.  Inebilizumab, a B Cell-Depleting Anti-CD19 Antibody for the Treatment of Autoimmune Neurological Diseases: Insights from Preclinical Studies , 2016, Journal of clinical medicine.

[81]  J. Verschuuren,et al.  Increased risk for clinical onset of myasthenia gravis during the postpartum period , 2016, Neurology.

[82]  R. Levy,et al.  Critical review of the current recommendations for the treatment of systemic inflammatory rheumatic diseases during pregnancy and lactation. , 2016, Autoimmunity reviews.

[83]  A. Vélez-van-Meerbeke,et al.  Human Immunoglobulin Versus Plasmapheresis in Guillain–Barre Syndrome and Myasthenia Gravis: A Meta-Analysis , 2016, Journal of clinical neuromuscular disease.

[84]  J. Howard,et al.  Effect of therapeutic plasma exchange on immunoglobulins in myasthenia gravis , 2016, Autoimmunity.

[85]  A. Marx,et al.  Randomized Trial of Thymectomy in Myasthenia Gravis. , 2016, The New England journal of medicine.

[86]  M. Benatar,et al.  International consensus guidance for management of myasthenia gravis , 2016, Neurology.

[87]  M. Benatar,et al.  A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis , 2016, Neurology.

[88]  H. Atkins,et al.  Myasthenia Gravis Treated With Autologous Hematopoietic Stem Cell Transplantation. , 2016, JAMA neurology.

[89]  V. Damato,et al.  3,4-Diaminopyridine may improve myasthenia gravis with MuSK antibodies , 2016, Neurology.

[90]  A. Sidawy,et al.  Thymectomy is safe for myasthenia gravis patients: Analysis of the NSQIP database , 2016, Muscle & nerve.

[91]  M. Benatar,et al.  Efficacy of prednisone for the treatment of ocular myasthenia (EPITOME): A randomized, controlled trial , 2016, Muscle & nerve.

[92]  A. Marx,et al.  Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society , 2016, Journal of Neurology.

[93]  H. Murai.  Japanese clinical guidelines for myasthenia gravis: Putting into practice , 2015 .

[94]  D. Allman,et al.  Subcutaneous veltuzumab, a humanized anti-CD20 antibody, in the treatment of refractory pemphigus vulgaris. , 2014, JAMA dermatology.

[95]  M. Filippi,et al.  Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis , 2014, Neurology.

[96]  J. Inazawa,et al.  Genetic variants in C5 and poor response to eculizumab. , 2014, The New England journal of medicine.

[97]  Jacqueline A Palace,et al.  Myasthenia in pregnancy: best practice guidelines from a UK multispecialty working group , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[98]  H. Ebadi,et al.  Safety of plasma exchange therapy in patients with myasthenia gravis , 2013, Muscle & nerve.

[99]  M. Pasnoor,et al.  Phase II trial of methotrexate in myasthenia gravis , 2012, Annals of the New York Academy of Sciences.

[100]  V. Bril,et al.  IVIG and PLEX in the treatment of myasthenia gravis , 2012, Annals of the New York Academy of Sciences.

[101]  V. Bril,et al.  Changes in quality of life scores with intravenous immunoglobulin or plasmapheresis in patients with myasthenia gravis , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[102]  M. Badri,et al.  A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis , 2011, BMC neurology.

[103]  V. Bril,et al.  Comparison of IVIg and PLEX in patients with myasthenia gravis , 2011, Neurology.

[104]  J. G. van Dijk,et al.  Clinical Dutch-English Lambert-Eaton Myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[105]  G. Vidarsson,et al.  The neonatal Fc receptor as therapeutic target in IgG-mediated autoimmune diseases , 2010, Cellular and Molecular Life Sciences.

[106]  V. Bril,et al.  A Comparison of the Effectiveness of Intravenous Immunoglobulin and Plasma Exchange as Preoperative Therapy of Myasthenia Gravis , 2008, Journal of clinical neuromuscular disease.

[107]  M. Pagala,et al.  Lifetime course of myasthenia gravis , 2008, Muscle & nerve.

[108]  L. Zinman,et al.  IV immunoglobulin in patients with myasthenia gravis , 2007, Neurology.

[109]  S. Fuchs,et al.  Blockade of CD40 Ligand Suppresses Chronic Experimental Myasthenia Gravis by Down-Regulation of Th1 Differentiation and Up-Regulation of CTLA-41 , 2001, The Journal of Immunology.

[110]  R. Barohn,et al.  Myasthenia gravis: recommendations for clinical research standards1 , 2000 .

[111]  S. Nagataki,et al.  Diagnostic significance of IgG, C3, and C9 at the limb muscle motor end‐plate in minimal myasthenia gravis , 1989, Neurology.

[112]  E. Brown,et al.  Accumulation of aluminium in chronic renal failure due to administration of albumin replacement solutions. , 1986, British medical journal.

[113]  A. Geurts,et al.  Strength training and aerobic exercise training for muscle disease. , 2005, Cochrane Database of Systematic Reviews.